📊 SIBN Key Takeaways
Is SI-BONE, Inc. (SIBN) a Good Investment?
SI-BONE demonstrates strong revenue growth (20.2% YoY) and exceptional gross margins (79.8%), indicating a viable medical device product with market traction. However, persistent negative operating cash flow (-2.4M) and operating losses (-5.1M) despite robust top-line growth raise concerns about cost structure and path to profitability, warranting a cautious stance pending operational improvements.
SI-BONE, Inc. Key Strengths (SIBN)
- Strong 20.2% YoY revenue growth with industry-leading 79.8% gross margins indicates robust product-market fit and pricing power
- Fortress balance sheet with 33.5M cash, low 0.20x debt/equity leverage, and 178.9M stockholders' equity provides substantial runway and financial flexibility
- Exceptional liquidity position (9.99x current ratio, 8.34x quick ratio) enables continued operations and strategic investments
SIBN Stock Risks: SI-BONE, Inc. Investment Risks
- Negative operating cash flow (-2.4M) and free cash flow (-3.4M) demonstrate ongoing cash burn despite revenue growth, threatening long-term viability if trend persists
- Operating margin of -9.7% and net margin of -8.2% reveal structural profitability challenges with inability to convert strong gross margins into operating income due to high expenses
- Negative operating income relative to debt load (interest coverage -5.8x) indicates operational earnings insufficient to service debt obligations
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Operating expense ratio relative to revenue growth rate to assess operating leverage
- Operating income trajectory toward profitability and margin expansion
- Cash burn rate and runway adequacy given current 33.5M cash position
SI-BONE, Inc. (SIBN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.99x current ratio provides a solid financial cushion.
SIBN Profit Margin, ROE & Profitability Analysis
SIBN vs Healthcare Sector: How SI-BONE, Inc. Compares
How SI-BONE, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is SI-BONE, Inc. Stock Overvalued? SIBN Valuation Analysis 2026
Based on fundamental analysis, SI-BONE, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
SI-BONE, Inc. Balance Sheet: SIBN Debt, Cash & Liquidity
SIBN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: SI-BONE, Inc.'s revenue has grown significantly by 123% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.13 indicates the company is currently unprofitable.
SIBN Revenue Growth, EPS Growth & YoY Performance
SIBN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $47.3M | -$4.3M | $-0.10 |
| Q3 2025 | $40.3M | -$4.6M | $-0.11 |
| Q2 2025 | $40.0M | -$6.2M | $-0.14 |
| Q1 2025 | $37.9M | -$6.5M | $-0.15 |
| Q3 2024 | $34.0M | -$6.6M | $-0.16 |
| Q2 2024 | $33.3M | -$8.9M | $-0.22 |
| Q1 2024 | $32.7M | -$10.9M | $-0.27 |
| Q3 2023 | $26.4M | -$10.0M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
SI-BONE, Inc. Dividends, Buybacks & Capital Allocation
SIBN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for SI-BONE, Inc. (CIK: 0001459839)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SIBN
What is the AI rating for SIBN?
SI-BONE, Inc. (SIBN) has an AI grade of B with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SIBN's key strengths?
Claude: Strong 20.2% YoY revenue growth with industry-leading 79.8% gross margins indicates robust product-market fit and pricing power. Fortress balance sheet with 33.5M cash, low 0.20x debt/equity leverage, and 178.9M stockholders' equity provides substantial runway and financial flexibility.
What are the risks of investing in SIBN?
Claude: Negative operating cash flow (-2.4M) and free cash flow (-3.4M) demonstrate ongoing cash burn despite revenue growth, threatening long-term viability if trend persists. Operating margin of -9.7% and net margin of -8.2% reveal structural profitability challenges with inability to convert strong gross margins into operating income due to high expenses.
What is SIBN's revenue and growth?
SI-BONE, Inc. reported revenue of $52.6M.
Does SIBN pay dividends?
SI-BONE, Inc. does not currently pay dividends.
Where can I find SIBN SEC filings?
Official SEC filings for SI-BONE, Inc. (CIK: 0001459839) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SIBN's EPS?
SI-BONE, Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SIBN's fundamental grade?
Based on our AI fundamental analysis in May 2026, SI-BONE, Inc. has a B grade with 55% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SIBN stock overvalued or undervalued?
Valuation metrics for SIBN: ROE of -2.4% (sector avg: 15%), net margin of -8.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SIBN's AI grade for 2026?
Our dual AI analysis gives SI-BONE, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SIBN's free cash flow?
SI-BONE, Inc.'s operating cash flow is $-2.4M, with capital expenditures of $1.1M. FCF margin is -6.5%.
How does SIBN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.2% (avg: 12%), ROE -2.4% (avg: 15%), current ratio 9.99 (avg: 2).